Induction and suppression of immediate-early genes in the rat brain by a selective alpha-2-adrenoceptor agonist and antagonist following noxious peripheral stimulation

The effect of medetomidine, a highly selective alpha-2-adrenoceptor agonist, on noxious stimulation-induced expression of immediate-early genes was studied in the central nervous system of the rat. The expressions of c-JUN, JUN B, c-FOS FOS B and KROX-24 proteins were investigated by immunocytochemistry following the application of formalin (5%, 50 microliters) into the plantar skin of one hindpaw. Medetomidine (100 or 300 micrograms/kg i.p.) was administered 12 min or 5 min before the application of formalin. Atipamezole (1.5 mg/kg i.p.), and alpha-2-adrenoceptor antagonist, administered simultaneously with medetomidine (300 micrograms/kg), was used to reverse the alpha-2-adrenergic effects. The rats were killed and perfused 90 min after formalin injection. Formalin induced expression of all studied proteins in the ipsilateral spinal dorsal horn and the contralateral parabrachial nucleus, and in the medial thalamus bilaterally. Both medetomidine doses administered 12 min before formalin strongly suppressed the expression of c-FOS in the spinal dorsal horn; the suppression was stronger in the deep (III-VI) than in the superficial (I and II) laminae of the dorsal horn (76% and 86% for 100 micrograms/kg dose vs 97% and 99% for 300 micrograms/kg dose, respectively). However, application of medetomidine 5 min before formalin did not reduce the expression of immediate-early genes. In the parabrachial nucleus, both medetomidine doses also produced a significant suppression of c-FOS expression (68%). In contrast, medetomidine at the dose of 100 micrograms/kg was ineffective in the medical thalamus. Only the higher dose of medetomidine (300 micrograms/kg) produced a suppression by 29% and 46% in centromedian and paraventricular nuclei, respectively. Atipamezole produced a significant attenuation in spinal cord and a complete reversal in parabrachial nucleus of the medetomidine-induced suppression. However, in the medial thalamus, atipamezole produced a dramatic increase of formalin-induced c-FOS expression when compared with formalin injection alone. The expression of c-JUN, JUN B, FOS B and KROX-24 proteins paralleled that of c-FOS. It is concluded that the expression of immediate-early gene encoded proteins is more strongly suppressed by alpha-2-adrenoceptor agonists in spinal and parabrachial than in medial thalamic neurons. The increased expression of immediate-early genes in medical thalamus following atipamezole treatment may be explained by increased release of noradrenaline and the consequent activation of alpha-1- and beta-adrenoceptors. Compared with the previously reported effects of behaviorally equipotent doses of morphine, the suppression of c-FOS expression in the spinal cord was stronger following medetomidine than that following morphine.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  H. Jalanka The use of medetomidine, medetomidine-ketamine combinations and atipamezole at Helsinki Zoo--a review of 240 cases. , 1989, Acta veterinaria Scandinavica. Supplementum.

[2]  M. Zerial,et al.  The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity. , 1989, The EMBO journal.

[3]  E. Kalso,et al.  Involvement of supraspinal and spinal segmental alpha-2-adrenergic mechanisms in the medetomidine-induced antinociception , 1991, Neuroscience.

[4]  H. Fields,et al.  Putative nociceptive modulatory neurons in the dorsolateral pontomesencephalic reticular formation , 1989, Brain Research.

[5]  J. Besson,et al.  Peripheral and spinal mechanisms of nociception. , 1987, Physiological reviews.

[6]  L. Lau,et al.  A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. North,et al.  Characterization of α2-adrenoceptors which increase potassium conductance in rat locus coeruleus neurones , 1985, Neuroscience.

[8]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[9]  J. Savola,et al.  Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. , 1988, European journal of pharmacology.

[10]  K. Berkley,et al.  Diencephalic mechanisms of pain sensation , 1985, Brain Research Reviews.

[11]  R. Tsien,et al.  α-Adrenergic inhibition of sympathetic neurotransmitter release mediated by modulation of N-type calcium-channel gating , 1989, Nature.

[12]  M. Scheinin,et al.  Behavioural and neurochemical effects of medetomidine, a novel veterinary sedative. , 1988, European journal of pharmacology.

[13]  D. Carter,et al.  Neurotransmitter-stimulated immediate-early gene responses are organized through differential post-synaptic receptor mechanisms. , 1992, Brain research. Molecular brain research.

[14]  M. Scheinin,et al.  Behavioural and neurochemical effects of antipamezole, a novel α2-adrenoceptor antagonist , 1988 .

[15]  B. Bean Neurotransmitter inhibition of neuronal calcium currents by changes in channel voltage dependence , 1989, Nature.

[16]  J. Savola,et al.  Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole. , 1989, Archives internationales de pharmacodynamie et de therapie.

[17]  M. Scheinin,et al.  Behavioural and neurochemical effects of atipamezole, a novel α2-adreneceptor antagonist , 1988 .

[18]  S. Hunt,et al.  Induction of c-fos-like protein in spinal cord neurons following sensory stimulation , 1987, Nature.

[19]  R. Dubner,et al.  Preproenkephalin mrna in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins , 1992, Neuroscience.

[20]  M. Kuhar,et al.  Distribution of α2 agonist binding sites in the rat and human central nervous system: Analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents , 1984, Brain Research Reviews.

[21]  P. Lemaire,et al.  Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Tanila,et al.  Effect of systemic medetomidine, an alpha 2 adrenoceptor agonist, on experimental pain in humans. , 1991, Anesthesiology.

[23]  R. Bravo,et al.  Specific temporal and spatial distribution of JUN, FOS, and KROX‐24 proteins in spinal neurons following noxious transsynaptic stimulation , 1991, The Journal of comparative neurology.

[24]  J. Besson,et al.  The spino(trigemino)pontoamygdaloid pathway: electrophysiological evidence for an involvement in pain processes. , 1990 .

[25]  W. Zieglgänsberger,et al.  Sequential expression of JUN B, JUN D and FOS B proteins in rat spinal neurons: Cascade of transcriptional operations during nociception , 1991, Neuroscience Letters.

[26]  K. Lynch,et al.  Distribution of α2-adrenergic receptor mRNAs in the rat CNS , 1991 .

[27]  M. Scheinin,et al.  Dexmedetomidine, an alpha 2-adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery. , 1990, Anesthesiology.

[28]  P. Gass,et al.  Induction of immediate early gene encoded proteins in the rat hippocampus after bicuculline-induced seizures: Differential expression of KROX-24, FOS and JUN proteins , 1992, Neuroscience.

[29]  Dept . Anatomy,et al.  Morphine or U‐50,488 suppresses fos protein‐like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat , 1992, The Journal of comparative neurology.

[30]  R. Bravo,et al.  Expression of different Jun and Fos proteins during the G0-to-G1 transition in mouse fibroblasts: in vitro and in vivo associations , 1991, Molecular and cellular biology.

[31]  E. Bullitt Expression of C‐fos‐like protein as a marker for neuronal activity following noxious stimulation in the rat , 1990, The Journal of comparative neurology.

[32]  J. Hieble,et al.  Structure and function of alpha-adrenoceptors. , 1991, Pharmacological reviews.

[33]  B. Mellström,et al.  Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene , 1991, Neuron.

[34]  J. Savola,et al.  Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. , 1991, European journal of pharmacology.

[35]  M. Zimmermann,et al.  The KROX-24 protein, a new transcription regulating factor: Expression in the rat central nervous system following afferent somatosensory stimulation , 1990, Neuroscience Letters.

[36]  E. Kalso,et al.  FLFQPQRF-amide modulatesα2-adrenergic antinociception in the rat dorsal horn in vivo , 1991, Brain Research.

[37]  J. Fairhurst,et al.  Adrenergic receptors mediate changes in c-fos mRNA levels in brain. , 1989, Brain research. Molecular brain research.

[38]  A. Pertovaara,et al.  The effect of medetomidine, an α2-adrenoceptor agonist, in various pain tests , 1990 .

[39]  H. Ruskoaho,et al.  EVIDENCE FOR MEDETOMIDINE AS A SELECTIVE AND POTENT AGONIST α2‐ADRENORECEPTORS , 1986 .

[40]  W. Zieglgänsberger,et al.  Opiates modify induction of c-fos proto-oncogene in the spinal cord of the rat following noxious stimulation , 1990, Neuroscience Letters.

[41]  T. Curran,et al.  Regulation of proenkephalin by Fos and Jun. , 1989, Science.

[42]  G. Bing,et al.  Noradrenergic activation of immediate early genes in rat cerebral cortex. , 1991, Brain research. Molecular brain research.

[43]  L. Lau,et al.  A gene activated by growth factors is related to the oncogene v-jun. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[44]  James I. Morgan,et al.  Role of ion flux in the control of c-fos expression , 1986, Nature.

[45]  M. Iadarola,et al.  In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Nahin,et al.  Spinal lamina I projection neurons in the rat: Collateral innervation of parabrachial area and thalamus , 1989, Neuroscience.

[47]  J. Wikberg,et al.  Rat Spinal Cord α2‐Adrenoceptors are of the α2A‐Subtype: Comparison with α2A‐ and α2B‐Adrenoceptors in Rat Spleen, Cerebral Cortex and Kidney Using 3H‐RX821002 Ligand Binding , 1991 .

[48]  A. Basbaum,et al.  The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: Correlation of nociceptive behavior and c-fos expression , 1991, Neuroscience.

[49]  A I Basbaum,et al.  Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[50]  J. Milbrandt,et al.  A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. , 1987, Science.

[51]  M. Scheinin,et al.  Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha-2-adrenoceptor agonist. , 1991, The Journal of pharmacology and experimental therapeutics.

[52]  T. Yaksh,et al.  Antinociceptive properties of intrathecal dexmedetomidine in rats. , 1991, European journal of pharmacology.

[53]  M. Dragunow,et al.  Kindling stimulation induces c-fos protein(s) in granule cells of the rat dentate gyrus , 1987, Nature.

[54]  H. Scheinin,et al.  The analgesic action of dexmedetomidine — a novel α 2-adrenoceptor agonist — in healthy volunteers , 1991, Pain.

[55]  E. Kalso,et al.  Spinal Antinociception by Dexmedetomidine, a Highly Selective α2-Adrenergic Agonist , 1991 .

[56]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[57]  A. Pertovaara Antinociception in bulboreticular neurons of the rat produced by spinally administered medetomidine, an alpha 2-adrenoceptor agonist. , 1991, European journal of pharmacology.